Orthotopic bladder substitution: Surgical aspects and optimization of outcomes by Thakare, N et al.
BJUI Compass. 2021;00:1–11.    |  1wileyonlinelibrary.com/journal/bco2
 
DOI: 10.1111/bco2.84  
R E V I E W
Orthotopic bladder substitution: Surgical aspects and 
optimization of outcomes
N. Thakare1  |   B. W. Lamb1,2 |   S. Biers1,2
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
© 2021 The Authors. BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company
Abbreviations: FS, frozen section; ISC, intermittent self- catheterization; LOS, length of stay; OBS, orthotopic bladder substitution; ONB, orthotopic neobladder; QoL, quality of life; 
RCT, randomized control trial; RC, radical cystectomy; RP, radical prostatectomy; UD, urinary diversion; WHO, World Health Organization.
1Department of Urology, Cambridge 
University Hospitals NHS Foundation Trust, 
Addenbrooke’s Hospital, Cambridge, UK
2Faculty of Health, Education, Medicine 
and Social Care, Anglia Ruskin University, 
Chelmsford, UK
Correspondence
S. Biers, Urology Consultant, Addenbrooke’s 
Hospital, Cambridge University Hospitals 




Objectives: Orthotopic bladder substitution (OBS) is a management option for uri-
nary diversion in men and women undergoing cystectomy. The aim of the procedure 
is to provide a functional continent urinary reservoir of adequate capacity, compli-
ance and low pressure. We have provided a narrative review of the existing literature 
and highlighted areas where improvement and standardization can be recommended.
Methods: Literature search included database search for publications from January 
1970 to November 2020, using keywords including OBS, bladder reconstruction, ne-
obladder, radical cystectomy, robotic cystectomy, intracorporeal neobladder, surgical 
technique, patient selection and outcomes.
Results: Due to various factors including indications, operative technique and risk 
of complications, OBS is an enormous undertaking and commitment for patients, 
surgeons and health professionals involved in the care pathway. The main considera-
tions for patient selection, the technical elements of the procedure and the rationale 
behind these are discussed. Previously considered to be a choice for a select few, the 
inclusion criteria have expanded over the last decade. Similarly, surgical techniques 
including the choice and configuration of bowel segments, construction of anasto-
mosis and nerve or organ sparing procedures have evolved over the years. Minimally 
invasive laparoscopic and robotic assisted surgery has added further perspectives to 
the existing literature on OBS. Understanding the principles of operative techniques 
and assessing the best evidence to influence patient management is crucial as it has a 
major impact on clinical outcomes. Peri- and post- operative care, focused on the pre-
vention of complications and morbidity, affects long- term functional and oncological 
outcomes, which ultimately dictates the quality of life.
Conclusions: This concise overview of OBS literature highlights the importance of 
pre- operative, peri- operative, and post- operative aspects with regards to the opti-
mization of patient care. To achieve the best results, meticulous attention should be 
paid in all these areas, surgical and multi- disciplinary. Patient education and coun-
seling, with shared decision making are central to the success of the procedure.
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1  | INTRODUC TION
The term orthotopic refers to a bladder substitute (neobladder) 
reconstructed in the same place as the native bladder, that is, in 
the pelvis. It is anastomosed to the native urethra, with a func-
tional external urethra sphincter providing the continence mech-
anism. Orthotopic bladder substitution (OBS) was first described 
for male patients after radical cystectomy for cancer in 1913 by 
Lemoine using rectum.1 Small intestine neobladder was first re-
ported by Camey and Le Duc in 1979.2 Use of an ileal segment is 
now the standard technique and radical cystectomy (RC) for blad-
der cancer is the main indication for OBS, which is less commonly 
performed for benign conditions including neurogenic bladder 
dysfunction.
In a consensus statement by the World Health Organization 
(WHO) and the Société Internationale d’Urologie (SIU), neobladder 
reconstruction was reported in 47% of patients undergoing radical 
cystectomy and urinary diversion.3 These figures were obtained 
from the institutions of the committee members from United States, 
Europe, Japan, and Egypt. This is highly disparate with the British 
Association of Urological Surgeons (BAUS) radical cystectomy audit 
2014/2015, which showed only 5.7% of cystectomy patients un-
derwent neobladder reconstruction.4 Similarly, recent reports from 
the United States National Cancer database show a declining trend 
toward continent diversion (12.1%) after radical cystectomy,5 likely 
due to the complexity of the procedure and concerns regarding the 
increased risk of complications with an increase in minimally invasive 
approaches.
Patients requiring RC are often referred from the center of initial 
diagnosis to a tertiary center for oncological management. An under-
standing of pre- operative considerations, operative techniques, and 
post- operative care is essential for the optimization of patients un-
dergoing neobladder reconstruction. We outline the fundamentals 
of OBS primarily in the context of radical cystectomy. The essential 
steps to prevent pitfalls from the beginning of the patient journey 
and to achieve long- term successful outcomes are discussed.
2  | METHODS
A Medline database search using the following keyword search 
criteria was performed: OBS, bladder reconstruction, neobladder, 
radical cystectomy, robotic cystectomy, intracorporeal neoblad-
der, surgical technique, patient selection, and outcomes. All pub-
lications from January 1970 to November 2020 were included and 
the literature search was confined to publications in English. An ad-
ditional manual search of references in relevant published articles 
was performed.
3  | PRE-  OPER ATIVE PL ANNING
Bladder substitution with intestinal segments is an option for con-
tinent diversion performed after cystectomy. The 2nd International 
Consultation on Bladder Cancer recommendations on the recon-
structive options after RC (2012), have outlined criteria for patient 
selection with regards to renal function and risk of secondary tumor.6 
Current EAU or AUA guidelines do not specifically offer recommen-
dations for patient selection for OBS and much of the evidence has 
evolved over the years. Indications include cancer, chronic inflam-
matory disease (tuberculosis, schistosomiasis, post- radiotherapy 
bladder contraction, bladder pain syndrome), and bladder dysfunc-
tion (neuropathic or idiopathic detrusor overactivity). OBS is very 
rarely performed for benign conditions and is mostly considered as 
a last resort when less invasive options have exhausted, in patients 
who wish to avoid an ileal conduit. The 2018- 2019 Hospital Episode 
Statistics (HES) database for NHS England reported a total of 2,165 
ileal conduit and 486 urinary diversion operations were performed 
with cystectomy that year, and only 46 were simple cystectomy 
(benign) procedures.7
3.1 | Oncological factors
For OBS following radical cystectomy, oncological aspects such as 
a complete resection of the primary tumor, negative margins, and 
the absence of metastatic disease are important. Pre- operative 
transurethral biopsies from the prostatic urethra in males and blad-
der neck in females have a high negative predictive value, although 
studies show that they are not as accurate as intra- operative frozen 
sections.8 Patients need clear counseling on the risk of developing 
secondary tumors in the urethra, which is 2.2% according to a sys-
tematic review by Fahmy et al.9 Recent studies show that patients 
with positive biopsies have an increased urethral recurrence rate, 
but the cancer- specific survival is not reduced.10
3.2 | Patient- related
Patient profile is of utmost importance and careful consideration 
of co- morbidities, performance status, life- expectancy, and cogni-
tive ability is needed. There is no age limit at which OBS can be of-
fered, and it has been suggested that elderly fit patients have similar 
outcomes to their younger counterparts.11 There is no oncological 
compromise to women undergoing urethral- sparing cystectomy.12 
Adequate renal and hepatic function is an absolute prerequisite 
to reduce the risk of metabolic complications associated with the 
presence of bowel in the urinary tract. Previous significant bowel 
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resection and severe inflammatory bowel disease predispose to the 
risks of Vitamin B12 deficiency, hyperoxaluria, and diarrhea, and 
hence are contra- indications. Well- informed motivated patients are 
ideal candidates as compliance with post- operative bladder training 
and a follow- up protocol is crucial.
3.3 | Functional considerations
Functional abnormalities of lower urinary tract including urethral 
strictures should be excluded. External urethral sphincter dysfunc-
tion and stress urinary incontinence are relative contraindications. 
Pelvic irradiation is not considered an absolute contraindication; 
however, continence rates are lower (56%- 76%).13,14 The risks of 
90- day post- operative complications are higher (77% vs. 52%) 
in non- neobladder UD with previous irradiation.13 Late sequelae 
such as bowel stenosis, spontaneous neobladder perforation, and 
neobladder- vaginal fistula were seen in 40% of OBS patients in 
this study. Patients should be counseled that additional continence 
procedures may be required, with artificial urinary sphincter being 
placed in around 20% of such patients.14 Prior radical prostatectomy 
is not a contraindication in men, especially if they have good conti-
nence pre- operatively.15
3.4 | Other factors
All options for urinary diversion including ileal conduit should be 
discussed with the patient and shared decision- making should be 
implemented. Involvement of a specialist nurse early on in the man-
agement pathway is essential. Initiation of the Enhanced Recovery 
Protocol for RC has shown to reduce median LOS from 14 days to 
7 days in the UK16 and improved overall outcomes by earlier return 
to normality.17 We have summarized the pre- operative factors to be 
considered prior to RC and OBS in Table 1.
4  | KE Y SURGIC AL PRINCIPLES
The main principle is to provide a continent urinary reservoir of ad-
equate capacity, compliance, and low pressure. The advantages are 
continence (and the avoidance of a stoma bag), potential for sponta-
neous voiding and improved body image.18
Careful dissection around the urethral margin to preserve the 
optimal length of urethra is necessary. Intra- operative frozen sec-
tion is recommended to confirm negative margins. Prostatic urethral 
tumors are associated with an increased risk of secondary urethral 
tumors (12%- 18%),19 and multifocal disease and carcinoma- in- situ 
(CIS) is also reported to increase the risk of prostatic urethral tumor 
and secondary urethral tumors. These factors were previously con-
sidered a contraindication to OBS, but studies show that they do 
not appear to significantly increase the risk of secondary tumor.9 If 
the distal urethral margin is negative intra- operatively, OBS can be 
performed.20,21 The incidence of urethral tumors is low in women 
undergoing cystectomy (1.4%), lower than for men (5%).9 Again, 
in appropriate cases, the suggestion is for frozen sections intra- 
operatively, and if negative, proceeding with OBS.22,23 If a frozen 
section shows tumor at bladder neck in women, the risk of develop-
ing urethral recurrence is 50%.22
4.1 | Choice of the bowel segment
Ileum is the most commonly used bowel segment as it has bet-
ter compliance and less contractility as compared with colon or 
cecum. Ileal neobladder can obtain the same capacity as a colonic 
TA B L E  1   Factors to be considered for pre- operative planning for orthotopic bladder substitution
Criteria Comments
Oncological • Resectable disease
• No lymph node involvement
• No distant/lung metastases
• Prostatic urethral biopsies in men negative
• Bladder neck biopsies in women negative
Positive biopsies increase the risk of urethral recurrence, 
but patients can still be considered for OBS as survival 
is not affected
Intra- operative FS more accurate






Renal and liver impairment and bowel disease are 
absolute contra- indications
A motivated fit ‘elderly’ patient is still a candidate
Functional • Exclude urethral stricture
• No sphincter dysfunction
• No stress urinary incontinence (SUI)
• Previous radical prostatectomy (RP)
• Previous pelvic radiation
Sphincter dysfunction and SUI are relative 
contraindications
Previous RP or radiotherapy is not contraindicated
Other • Enhanced Recovery Protocol
• Shared decision making
• Specialist nurse input
Desirable factors
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neobladder, but ileal storage pressures are lower,24 and there is less 
reabsorption of components from the urine due to mucosal atrophy 
over time, as compared to colon. Other segments of the intestine 
that have been used include ileum with cecum and or colon (Mainz 
pouch, Le Bag), right colon (Indiana, Goldwasser), and sigmoid. A 
meta- analysis of two trials suggested no difference in daytime or 
nocturnal continence rates between ileocolonic segments (using the 
Le Bag technique) or ileocaecal segments compared with and ileal 
segment (using the Studer technique).25,26 Only one trial was identi-
fied that suggested ileal neobladder had lower rates of nocturnal in-
continence, compared to ileocolonic segments,26,27 the other study 
did not identify any differences.25
4.2 | Techniques of bowel configuration
The chosen bowel segment is detubularized and the segments are 
reconfigured to create a spherical- shaped reservoir. This obtains 
the maximal volume from the minimum absorptive surface area of 
bowel. Detubularization also lowers the reservoir pressure, reducing 
the risk of vesicoureteric reflux, and lowers the risk of spontaneous 
contractions causing urinary leak. However, it also increases the risk 
of requiring intermittent self- catheterization (ISC). Examples of ileal 
neobladder include the Studer, Hautmann, Vescica ileale Padovana 
(VIP), Orthotopic Kock pouch (or hemi- Kock), and Camey II neoblad-
der. Table 2 gives a brief summary of the techniques used in bladder 
reconstruction. The Studer pouch (with various modifications) is the 
most commonly used technique as it is relatively easier to perform.
4.3 | Urethral and ureteric anastomoses
Anastomosis between the reconstructed bladder outlet and the ure-
thra (preserving the sphincter) is created in a manner that it sits flat in 
the pelvis. A funnel- shaped outlet is not favored as it has risk of kinking 
and mechanical obstruction. This is especially important in women as 
urethral- pouch flexion can lead to chronic retention.28 As described 
by Studer, the reservoir can be held in place by anchoring sutures to 
the Denonviller's fascia and pubo- prostatic ligaments. This allows 
for minimal tension on the membranous urethra and urethro- pouch 
anastomosis. The ureters are mobilized, and implantation is achieved 
by an end- to- side anastomosis either directly into the reservoir or into 
an afferent tubular limb as described by Studer.29 Temporary ureteric 
catheters are inserted and brought to the abdominal wall to divert the 
urine and protect the anastomotic suture line from leaks.30
4.4 | Anti- reflux mechanism
The question of whether reflux in a low- pressure reservoir such as 
OBS is clinically important has been debated. The WHO Consensus 
Group reported that reflux is not of clinical importance in OBS, but an 
anti- reflux mechanism is essential in continent cutaneous pouches.3 
Other studies indicated a trend toward an increased risk of stenosis 
(and subsequent upper tract deterioration) with anti- refluxing versus 
freely refluxing uretero- intestinal anastomotic techniques in OBS.31,29 
One study randomized ileal OBS patients to either anti- refluxing nip-
ple valve or an isoperistaltic afferent ileal tubular segment for reflux 
TA B L E  2   Techniques of bladder reconstruction using bowel segments
Technique Bowel segment Principle
Studer Ileum 60 cm terminal ileum isolated (25 cm away from ileocaecal valve); 40 cm used to form a 
reservoir; 20 cm used to form the afferent tubular limb for anastomosis of ureters (to 
prevent reflux)
Hautmann W Pouch Ileum 70 cm of ileum incised along the antimesenteric border and arranged into a ‘W’ 
configuration. Ureters are reimplanted from inside the neobladder via a small incision 
and are non- refluxing
Vescica ileale Padovana (VIP) Ileum 40 cm segment of ileum is isolated (15- 20 cm away from the ileocaecal valve). The 
detubularized ileum is fashioned in a circular manner to create a spherical reservoir. The 
ureters are spatulated and passed through the posterior aspect
Orthotopic Kock Pouch Ileum 60 cm ileum; the proximal 16cm is used for making the afferent nipple Two long 
segments are used to construct a ‘U’ shape, and an ileal plate is made. A mesenteric 
window is created at the proximal aspect of the afferent limb, which is intussuscepted 
onto the ileal plate and stapled in place. The ureters are stitched to the proximal part of 
the afferent limb with the Wallace technique
Camey II Ileum 65 cm of ileum is isolated, detubularized, and configured unto a ‘U’ shape. The 
neobladder is attached to the urethra in the mid- point and laterally fixed to the pelvic 
side wall. Non- refluxing ureteric re- implantation is performed into the lateral limbs of 
the reservoir
Mainz Pouch Ileocolonic 10- 15 cm cecum and ascending colon and 20- 30 cm terminal ileum are isolated and 
detubularized, and anastomosed side- to- side to create a pouch
Indiana Pouch Right colon Detubularized right colon used
Note: Of note, the Koch nipple valve is no longer in common use because of an increased rate of complications.
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prevention.29 After a median 45- 57 months follow- up, there was no 
difference in the incidence of urinary tract infection (UTI), urinary 
incontinence, serum creatinine or functional reservoir capacity be-
tween the two groups. However, stenosis and upper tract deteriora-
tion were higher with the anti- refluxing technique (13.5% vs. 3% in the 
refluxing group).29 When strictures do occur, they are associated with 
renal impairment.31 Currently, oncological surgeons, who perform 
OBS, omit the formation of an anti- refluxing mechanism.
4.5 | Nerve sparing and organ sparing
Nerve- sparing in men is performed using the same technique as 
radical prostatectomy by dissection of the plane between the pro-
static capsule and the neurovascular bundle. Nerve sparing can 
be unilateral on the non- tumor bearing side so that oncological 
safety is not compromised. In both male and female patients, pres-
ervation of autonomic innervation has a positive impact on con-
tinence with long term benefits.32,33 Similarly, nerve sparing also 
prevents erectile dysfunction in men and loss of sexual function in 
women.34,35 In women, genital sparing surgery is recommended as 
it is known to maintain continence and sexual function,36 although 
further studies are required to assess its benefit over standard 
RC.37 Preservation of the anterior vaginal wall has been shown 
to improve function, without compromising negative margins.38 
Prostate capsule and seminal vesical preserving procedures were 
previously discouraged due to poorer functional and oncological 
outcomes.39,40 Recent studies, however, suggest that in select 
cases prostate capsule sparing has shown better continence and 
erectile function rates, with similar oncological outcomes.41 In 
one recent study, functional outcomes, at 3 months after surgery, 
90% of men reported daytime urinary continence in the prostate 
capsule sparing group versus 51% in the non- sparing groups and 
53% versus 9% patients showed erectile function recovery.42 A 
systematic review by Hernández et al, concluded that in men, sex-
ual function preserving cystectomy including prostate- , seminal 
vesicle- and nerve- sparing showed higher potency rates.43
4.6 | Minimally invasive techniques
With the advent of minimally invasive and robotic- assisted surgery, 
techniques for ONB reconstruction have also shown advancement, 
though the basic principles remain the same. Robotic cystectomy 
and extracorporeal neobladder formation involve the construction 
of the ileal pouch in an open manner followed by urethro- enteric 
anastomosis performed with the robot using the “Van Velthoven 
technique”.44 The Karolinska- modified Studer neobladder tech-
nique, a total intracorporeal robotic neobladder reconstruction 
using Ligaloop bands was pioneered by Jonsson et al.45 Other in-
tracorporeal robotic neobladders described in large series include 
the University of Southern California– modified Studer neobladder, 
the pyramid pouch, and the Y- pouch.46 Whether intracorporeal 
approach has advantages in terms of post- operative recovery, is not 
fully established, reports have shown a longer learning curve and 
slightly higher risk of complications compared to extracorporeal di-
version.47,48 The currently ongoing iROC trial is a prospective RCT 
comparing outcomes of robotic cystectomy and intracorporeal di-
version with the outcomes of open RC.49 One study comparing open 
with robotic intracorporeal neobladders showed that short- term 
results for urodynamics and Health- related quality of life (HRQoL) 
score were similar, although daytime incontinence was worse for in-
tracorporeal ONB.50 The authors ascribed this to the shorter period 
of post- operative recovery in the robotic group.
Figure 1 shows illustrations of the commonly performed ileal 
neobladder variants including Studer, Hautmann, VIP, and the ro-
botic intracorporeal Karolinska- modified Studer pouch.
5  | POST-  OPER ATIVE C ARE AND 
COMPLIC ATIONS
In the post- operative period, management of catheters is important, 
with regular flushing and removal of mucus and blood clots from the 
neobladder. Removal of ureteric and suprapubic catheter depends 
upon institutional practice and there is no consensus on the place-
ment or duration of catheters. As per Studer's original description,51 
the ureteric catheters can be removed between 5 and 8 days post-
 op and a cystogram performed at 8 to 10 days with removal of su-
prapubic catheter followed by urethral catheter removal 48 hours 
later. After the removal of catheters, patients are trained to void 
and undergo a period of bladder rehabilitation. Voiding is initiated 
by relaxing the sphincter and pelvic floor, while gently increasing 
intra- abdominal pressure. Gradual increase in neobladder capacity 
is achieved by increasing the intervals between voids. Post- void re-
siduals are measured to ensure emptying although there are no strict 
cut- offs for ideal residual volumes. Positive urine culture occurs in up 
to 10% of patients due to resident bowel flora. Incomplete emptying, 
excess mucous production and upper tract obstruction should be 
excluded and must be treated with antibiotics even if asymptomatic. 
A systematic review of urinary diversions showed that OBS had 
lower postoperative morbidity (14%) and mortality (1%) as compared 
to ileal conduit (21% morbidity and 2% mortality rate), although this 
did not reach statistical significance.52 It could be argued that these 
differences were due to selection bias involved in patients undergo-
ing different types of urinary diversions. Overall early complications 
(within 30 days post- operatively) in ileal neobladders are reported in 
around 23%.53 The MSKCC standardized reporting system54 defines 
11 categories of post- RC complications as summarized in Table 3.
6  | FOLLOW- UP AND LONG - TERM 
MANAGEMENT
The aim of follow- up is the early detection of metabolic com-
plications, management of voiding and sexual dysfunction and 
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surveillance for cancer recurrence. There are no specific guidelines 
for post- OBS follow- up, and most regimes are guided by radical cys-
tectomy follow- up protocols as per the published EAU guidelines.55 
Generally, a combination of urine culture (for UTIs), bloods tests 
(to assess for renal, hepatic function, and metabolic complications), 
post- void residuals, upper tract imaging, voiding diary, and question-
naires is advocated.
Late complications (summarized in Table 3) are reported in 
13% at a median follow- up of 48 months, and in 31% at a median 
of 88 months follow- up.56 A Cochrane Review reported no statis-
tical difference in the incidence of UTI, uretero- intestinal stenosis, 
and renal deterioration between OBS and other forms of urinary 
diversion.27 OBS is reported to have a median rate of lower UTI 
of 9%- 45%; upper UTI in 4%- 14%; requirement for ISC in 9%- 10%; 
urolithiasis in 5%- 7%; Vitamin B12 deficiency in 5%; diarrhea in 1% 
and re- operation rate in 7%- 8%. The incidence of uretero- intestinal 
stricture is between 5% and 11%.51 Other reported complications in-
clude mucus production, neobladder, and upper urinary tract stones, 
vaginal- neobladder fistula, and OBS rupture.
Declining renal function can occur after OBS with 31%, 57%, 
and 74% risk of deterioration over 1, 5, and 10 years of follow- up, 
which is similar to ileal conduit diversion and can be reduced by 
identifying modifiable factors such as post- operative pyelonephri-
tis, hydronephrosis and uretero- enteric anastomotic stricture.56 
Metabolic disturbances are dependent on the types of bowel 
segment used. Long- term studies suggest a risk of around 4.5%.57 
Ileum and colon can produce a hyperchloremic metabolic acidosis; 
jejunum can produce a hypochloremic, hyperkalemic metabolic 
acidosis and is less commonly utilized. While the majority do not 
need active treatment for this, sequelae of acidosis may include 
other electrolyte abnormalities, altered hepatic metabolism, os-
teomalacia, osteoporosis, urolithiasis, altered drug metabolism. 
Severe acidosis can lead to lethargy, vomiting and can be treated 
with fluids and alkalinization therapy with sodium bicarbonate for 
small bowel reservoirs and potassium citrate for large bowel res-
ervoirs. Refractory cases of acidosis may be treated with chloride 
transport blockers (such as chlorpromazine). Chronic metabolic 
acidosis and bone loss can result in a 21% increased risk of frac-
tures in RC patients.58
6.1 | Functional outcomes
From a reconstructive aspect, a focus on functional outcomes is 
necessary as continence and sexual function contribute hugely to 
quality of life. Across several studies, continence is not uniformly de-
fined, and therefore continence rates are difficult to quantify mainly 
because of the heterogenicity of data. Overall continence rates are 
reported at around 85%.59 Daytime continence rates are reported to 
be between 89% and 99%.53,60– 64 As well as continued bladder reha-
bilitation to increase neobladder capacity, pelvic floor rehabilitation 
is recommended in the form of pelvic floor muscle training super-
vised by a specialist nurse or physiotherapist. Despite a satisfactory 
operative technique and peri- operative care, incontinence can be 
F I G U R E  1   Diagrammatic representation of the commonly performed ileal neobladder variants. (I) Studer pouch, (II) Hautmann, 
(III) Vescica ileale Padovana (VIP) and (IV) Robotic intracorporeal Karolinska- modified Studer pouch
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caused by overactivity in neobladders. Although the exact mecha-
nism of overactivity is not known, pharmacological treatments in-
cluding anticholinergics, imipramine, and intravesical Botulinum 
Toxin A have been tried.65 Nocturnal continence takes longer to 
return, up to 24 months, and is reported to affect 74%- 83%.53,60– 64 
Nocturnal incontinence occurs due to the absence of the physiologi-
cal detrusor sphincter reflex, decreased tone of urethral sphincter, 
and uninhibited neobladder contractions at night.66 Verapamil and 
oxybutynin have been shown to improve nocturnal continence 
rates.67 Continence rates after robotic intracorporeal neobladder 
construction are similar with up to 88% overall continence in one 
series68 and 87% daytime with 80% nocturnal continence in another 
large series.69
Continence does appear to be maintained in the longer- term. In a 
study including three centers all performing ileal neobladders (Studer, 
Hautmann W Pouch or T pouch), at a mean follow- up of 48 months, 
daytime and nocturnal continence rates were 99% and 78%, re-
spectively.63 In the same patient group, follow- up for a mean of 
88 months, 98% of patients were still achieving daytime continence 
and 76% were maintaining nocturnal continence.53 Maintenance 
of continence in women after a median of 6.1 years follow- up re-
mained good with 82.4% daytime continence and 76.5% nocturnal 
continence.70 Of note, 58% of women in this study required periodic 
ISC. Women fare slightly less well overall than men, with daytime 
continence rates around 72%- 87%, and nocturnal continence around 
66%- 85%.12,23,38,70,71 Complete continence is reported in 57%, of the 
remainder using pads, 66% used 1- 2 pads per day.23
The 2012 Cochrane review of urinary diversion and bladder re-
construction identified studies indicating 0%- 70% of patients who 
require ISC, while the remainder are able to empty the neobladder 
by abdominal straining.27 Rates of ISC for the Studer neobladder are 
around 0%- 21%.53,62,72,73 In women, urinary retention (requiring ISC) 
is reported in 25%- 50%.12,23,60,74,75
Rates of erectile dysfunction in men without nerve- sparing have 
been reported to be around 35% at 12 months follow- up and are 
higher than that for ileal conduit (9.8%).76 Women commonly en-
counter sexual dysfunction with reported dyspareunia (22%), re-
duced libido (37%), difficulty achieving orgasm (45%), and decreased 
lubrication (41%).77 Reported studies show mixed results and as dis-
cussed above nerve- sparing and organ- sparing are beneficial.
TA B L E  3   Summary of complications in patients undergoing Radical Cystectomy and Orthotopic Bladder Substitution
Post- operative/Early complicationsa 
Gastrointestinal (29%) Ileus, small bowel obstruction, anastomotic bowel leak, constipation, diarrhea, GI bleeding
Infectious (25%) UTI, urosepsis, sepsis, pyelonephritis, abscess
Wound (15%) Infection, wound dehiscence
Genitourinary (11%) Urinary leak, fistula, renal failure, hematuria, retention, ureteric obstruction
Cardiac (11%) Myocardial infarction, heart failure, arrhythmia
Pulmonary (9%) Chest infection, atelectasis, pleural effusion, pneumothorax
Bleeding (9%) Wound hematoma, post- operative bleed
Thromboembolic (8%) DVT, PE
Neurological (5%) CVA/TIA, seizures, delirium, peripheral neuropathy
Miscellaneous (3%) Psychological, dermatitis, tendonitis, acidosis, lymphocele, dehydration
Surgical (1%) Bowel injury, vascular injury, incisional hernia
Long term/Late complications
Urinary UTI (upper 4%- 14%; lower 9%- 45%)
Urolithiasis (5%- 7%)
Uretero- intestinal stricture (5%- 11%)
Renal function Gradual decline in eGFR (31%- 74%)
Metabolic Metabolic acidosis 4.5% [hypokalaemic hyperchloremic in ileal and hypochloraemia in jejunal 
neobladder]
Vitamin B12 deficiency (5%)
Osteoporosis; osteomalacia and hyperphosphatemiab 
Hepatic dysfunctionb 
Risk of fractures (21%)
Functional Urinary Incontinence (12%- 15%)
Urinary Retention/incomplete bladder emptying requiring ISC (0%- 21%; up to 50% in women)
Erectile dysfunction (35%)
Female sexual dysfunction (45%)
aEarly complications: within 0- 90 days as per MSKCC standardized reporting; bNo studies reporting %age risk.
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6.2 | Oncological outcomes
From an oncological perspective, there is no specific schedule rec-
ommended for follow- up due to the limited data on surveillance.78 
Recurrence is treated with urethrectomy and either ileal conduit or 
further reconstruction. Reconstruction involves closure of bladder 
neck and formation of a continent catheterizable channel via a cuta-
neous stoma. CIS may be treated with intraurethral BCG perfusion 
therapy.79 The risk of urethral tumor recurrence is lower for OBS 
than for cutaneous diversions. A recent systematic review showed 
that the risk of urethral recurrence was 2.2% with ONB versus 5.5% 
in non- ONB urinary diversion.9 The authors concluded that muscle 
invasion, CIS, and prostatic stromal or urethral involvement at the 
time of RC have no significant effect on recurrence. There is some 
evidence that in male patients with symptomatic urethral recur-
rence, the survival rate is lower than those with no symptoms.80 
EAU guidelines suggest that recurrence is more common within 
the first few years and recommend 6 monthly CT scans for 3 years 
followed by annual imaging. The Randomized Open versus Robotic 
Cystectomy (RAZOR) trial demonstrated that robotic RC is non- 
inferior to open RC in terms of oncological outcomes.81 All urinary 
diversions in this trial were extracorporeal, performed using an open 
technique.
7  | QUALIT Y OF LIFE (QoL)
Overall QoL remains good in most patients with OBS, with few 
differences between different types of diversion.3,82,83,84 Health- 
related quality of life (HRQoL) tested by the Short Form- 36 and a 
functional index questionnaire comparing orthotopic substitution 
with ileal conduit after radical cystectomy were favorable in both 
groups after a median follow- up of 12- 15 months.59 While OBS pa-
tients had overall higher (favorable) mean scores for most param-
eters, there was no significant difference in most QoL indices, but 
issues with regards to body image were persistent in a patient with 
ileal conduit diversion. Ileal neobladder (Studer) patients had a sig-
nificantly better physical function and a more active lifestyle (96% in 
OBS vs. 68% in the ileal conduit group).59
A few studies have shown an increased benefit in QoL spe-
cifically with OBS,18,85,86 with significantly better adaptation, 
self- confidence and rehabilitation compared to ileal conduit, and im-
proved return to normal activities. Patients who had OBS are more 
likely to recommended it as the preferred type of urinary diversion 
(97% vs 36% of conduit patients). Some report greater concern from 
ileal conduit patients regarding urinary leakage and adversely al-
tered body image,87 and around 48.5% of patients had wet clothes 
due to urinary leakage during the day, versus 1.5% of neobladder 
patients.18,85 Male patients having undergone OBS, have shown 
improved libido (47% vs. 21%) and erections as compared to ileal 
conduit (42% vs. 25%), although both groups reported similar low 
satisfactory sexual intercourse.59
At medium- term (5- year) follow- up (mean 89 months), general 
health QoL was generally well maintained as compared to the “nor-
mal” population, unless patients required ISC or suffered from day-
time incontinence.88 Studies reviewing QoL at 8.3 years follow- up 
found no difference between ileal conduit and continent diversion 
although QoL scores tend to be lower for older patients, particularly 
over the age of 80 years.89
Several studies have assessed and compared the quality of life in 
patients undergoing different types of urinary diversion. Validated 
questionnaires such as EORTC QLQ- 30C, SF- 36, and FACT(- BL) (- G) 
(- VCI) do not necessarily focus on the type of urinary diversion or 
specific functional outcomes and sexual function. Health- related 
quality of life (HRQoL) was previously reported to be only margin-
ally better with OBS compared to Ileal conduit diversion.90 A further 
meta- analysis of non- RCTs showed a clear benefit of OBS over ileal 
conduit in terms of HRQoL.91 The impact on the quality of life can 
also be assessed by the level of regret experienced after undergoing 
a certain type of diversion. Recent evidence comparing OBS with 
ileal conduit shows that shared decision- making and goal concor-
dance is necessary to achieve a low level of decision regret.92 Thus, 
is it vital that treatment outcomes should be discussed with patients 
and the choice to proceed with OBS made in an informed manner.
8  | CONCLUSIONS
OBS is a valuable surgical option with the possibility of restoring the 
lower urinary tract function to achieve continence. This is important 
for patients undergoing RC as the “loss of an organ” is somewhat com-
pensated by the psychological benefit of a “new one.” Over the years, 
indications for OBS have been refined and if strategically organized, 
the interplay between operative techniques and post- operative care 
can lead to the most successful results. Further research is required 
in areas of minimally invasive techniques and standardization of 
long- term management. Patients should be appropriately counseled 
regarding the long- term outcomes and impact on the quality of life. 
Above all, the type of urinary diversion should be acceptable to the 
patient whose main concern is cancer recurrence.
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